FDA approves first biosimilar for treatment of certain breast, stomach cancers

Share

Shares of Biocon rallied 15% after the drug regulator, USFDA approves Mylan and Biocon's co-developed product, Ogivri, the first biosimilar for Trastuzumab for treatment of HER2-Positive breast and gastric cancers.

"The FDA continues to grow the number of biosimilar approvals, helping to promote competition that can lower health care costs".

Sunny Monday To Be Followed By Rain - Maybe Snow - Later In Week
The forecaster has said that the country will experience a colder weather front from Wednesday onwards. A northwest wind will be 13 to 18 miles per hour , with gusts as high as 28 miles per hour .

Gottlieb added that the FDA is "committed to taking new policy steps to advance our biosimilar pathway and promote more competition for biological drugs".

Mylan and Biocon announced that the European Medicines Agency (EMA) has accepted a resubmitted application for their Herceptin biosimilar, as well as one for their copy of Amgen's chemo drug, Neulasta. Biocon has co-exclusive commercialization rights with Mylan for the product in the rest of the world.

Bitcoin Regulation: Why the UK Treasury Stepping in Will Not Stop Criminals
Bitcoin now works by anonymous trading, which has fuelled fears that it could be an attractive way of funding illegal activity. An EU-wide plan will force Bitcoin trading platforms to monitor transactions and report any that seem suspicious.

Ogivri's clearance is based on a review of evidence that included extensive structural and functional characterisation, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates its biosimilarity to Herceptin (trastuzumab).

Mylan said in a statement Ogivri is the first biosimilar in its collaboration with Biocon to get U.S. approval, and while it has kept quiet about its commercialisation plans some analysts have suggested it will start making revenues from the drug in 2019 - the year in which Roche's United States patent on Herceptin expires. This was first ever biosimilar made by an India drug maker to get a US FDA nod.

Ten arrested over murder of journalist Daphne Caruana Galizia
Following the death, the Maltese government offered a €1m (£890,000) reward for information about Caruana Galizia's murder. But the 53-year-old also focused attention on alleged murky behaviour by prominent opposition and business figures.

Shares of Biocon settled with gains of 15 per cent on the bourses, after the company said it has received regulatory approval to market a biosimilar of cancer drug Herceptin in the USA, following which the market capitalisation of the company improved by Rs 4,020 crore.

Share